HomeSHTDY • OTCMKTS
add
Sinopharm Group ADR
Previous close
$12.22
Day range
$12.75 - $13.08
Year range
$10.13 - $16.31
Market cap
63.19B HKD
Avg Volume
44.99K
Market news
Financials
Income Statement
Revenue
Net income
(CNY) | Jun 2024info | Y/Y change |
---|---|---|
Revenue | -122.51B | -0.93% |
Operating expense | -6.47B | -5.44% |
Net income | -419.63M | 30.73% |
Net profit margin | 0.34 | -32.00% |
Earnings per share | — | — |
EBITDA | -2.33B | 20.26% |
Effective tax rate | 26.07% | — |
Balance Sheet
Total assets
Total liabilities
(CNY) | Jun 2024info | Y/Y change |
---|---|---|
Cash and short-term investments | 8.62B | -74.94% |
Total assets | 33.55B | -91.97% |
Total liabilities | 15.61B | -94.87% |
Total equity | 17.94B | — |
Shares outstanding | 3.12B | — |
Price to book | 2.36 | — |
Return on assets | -2.64% | — |
Return on capital | -5.30% | — |
Cash Flow
Net change in cash
(CNY) | Jun 2024info | Y/Y change |
---|---|---|
Net income | -419.63M | 30.73% |
Cash from operations | 46.42B | 14.53% |
Cash from investing | -362.06M | 22.79% |
Cash from financing | -23.30B | -6.05% |
Net change in cash | 22.75B | 25.76% |
Free cash flow | 103.16B | 370.65% |
About
Sinopharm Group Co., Ltd. is a Chinese pharmaceutical company. The parent company of Sinopharm Group was Sinopharm Industrial Investment, a 51–49 joint venture of state-owned enterprise China National Pharmaceutical Group and civilian-run enterprise Fosun Pharmaceutical.
Its H shares were listed on the Hong Kong Stock Exchange in 2009, with its IPO price of HK$16 per share. Sinopharm Group's subsidiary Sinopharm CNMC and Sinopharm Accord served as the A share counterpart of the company. However, the A share of Sinopharm Group itself was unlisted.
Sinopharm Group was ranked 829th in 2016 Forbes Global 2000 list. Wikipedia
Founded
2003
Website
Employees
113,635